タイトル |
-
en
Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
|
作成者 |
|
アクセス権 |
open access |
権利情報 |
-
en
This is the peer reviewed version of the following article: Asano, T., Hirano, S., Nakamura, T., Okamura, K., Tsuchikawa, T., Noji, T., Nakanishi, Y., Tanaka, K. and Shichinohe, T. (2018), Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. J Hepatobiliary Pancreat Sci, 25: 342-350., which has been published in final form at https://doi.org/10.1002/jhbp.565. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
|
主題 |
-
Other
en
Conversion surgery
-
Other
en
Multidisciplinary treatment
-
Other
en
Prognosis
-
Other
en
Survival analysis
-
Other
en
Unresectable pancreatic cancer
-
NDC
490
|
内容注記 |
-
Abstract
en
Background: Conversion surgery (CS) is expected as a new therapeutic strategy for patients with unresectable pancreatic cancer (UR-PC). We analyzed outcomes of CS for patients with UR-PC and evaluated the survival benefit of CS. Methods: Thirty-four patients diagnosed with UR-PC according to the National Comprehensive Cancer Network guideline underwent CS in our hospital. Resectability was considered by multimodal images in patients who underwent nonsurgical treatment (NST) for more than 6 months. CS was performed only in patients who were judged to be able to undergo R0 resection. Results: Twenty-six patients had locally advanced PC, and eight had distant metastases. The median duration of NST was 9 (range 5-44) months. R0 resection was achieved in 30 patients (88.2%). Six patients (17.6%) showed Evans grade ≥III. Three- and 5-year overall survival (OS) rates from initial treatment were 74% and 56.9%, respectively, with median survival time (MST) of 5.3 years. The actual 5-year OS rate in 19 patients was 47.4% with an MST of 4.0 years. Patients with Evans grade ≥III had a better prognosis than those with Evans grade <III (P = 0.0092, log-rank test). Conclusions: Conversion surgery might have survival benefits to patients with UR-PC who responded favorably to NST.
|
出版者 |
en
John Wiley & Sons
|
日付 |
|
言語 |
|
資源タイプ |
journal article |
出版タイプ |
AM |
資源識別子 |
HDL
http://hdl.handle.net/2115/74831
|
関連 |
-
isVersionOf
DOI
https://doi.org/10.1002/jhbp.565
-
PMID
29797499
|
収録誌情報 |
-
-
en
Journal of hepato-biliary-pancreatic sciences
-
巻25
号7
開始ページ342
終了ページ350
|
ファイル |
|
コンテンツ更新日時 |
2023-07-26 |